554723
ATRA-BA Hybrid
4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124
Wenn Sie allgemeine Fragen haben, wenden Sie sich bitte an unseren Kundenservice:
Merck Chemicals Ltd.
Padge Road, Beeston
NG9 2JR Nottingham
United Kingdom
Telefon: +44 (0)115 9430840
Fax: +44 (0)115 9430951
E-Mail: customer.service@merckbio.eu
26 Mai 2013
wird geladen
The differentiation-inducer all-trans-Retinoic Acid (ATRA; Cat. No. 554720) and the histone deacetylase inhibitor (HDI) Butyric Acid (BA; Cat. No. 567430) are incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to facilitate their cellular uptake and to better synergize their cancer killing potency. The growth inhibitions of PC-3 and MDA-MB-231 by the MP (IC50 = 1.02 and 0.01 µM, respectively) are much superior to those achieved by separate (IC50 = 7.6 and 10.85 µM, respectively, with ATRA; IC50 = 72.44 and >1000 µM, respectively, with BA) or combined dosing of ATRA/BA (55% vs. 30% PC-3 growth inhibition by 10 µM MP vs. co-treatment of 10 µM each of ATRA & BA). At 37°C, VNLG/124 is completely converted to ATRA and BA within an hour in fresh murine plasma, but is otherwise stable for more than 24 hours in the absence of esterase activity in 20 mM PBS.
| Produktinformationen | |||
|---|---|---|---|
| Form | Yellow solid | ||
| Molare Masse | 476.7 | ||
| Protect from Light | Ja | ||
| Protect from Moisture | Ja | ||
| Packaged under inert gas | Ja | ||
| Purity | ≥95% by HPLC | ||
| Löslichkeit in Wasser | DMSO | ||
| Chemische Formel | C31H40O4 | ||
| Lager- und Versandinformationen | |||
|---|---|---|---|
| Lagerkategorie | -20°C | ||
| Ship |
Shipped with Blue Ice or with Dry Ice
Harmful |
||
| Sicherheitshinweise | |||
|---|---|---|---|
| S-Satz |
S: 22-26-36-45 |
||
| R-Satz |
R: 22-36/37/38-63 |
||
